呼吸器疾患 診断治療アプローチ 4 間質性肺炎・肺線維症と類縁疾患

出版社: 中山書店
著者:
発行日: 2018-10-01
分野: 臨床医学:内科  >  呼吸器一般
ISBN: 9784521745282
電子書籍版: 2018-10-01 (初版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

12,100 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

12,100 円(税込)

商品紹介

間質性肺炎のなかでも原因が特定できない特発性間質性肺炎は,病態により経過・治療法が異なるため,早期の診断が重要となる.本書では特発性間質性肺炎を中心に,病因・病態論における基礎研究の最新知見,診断の進め方,各種病態およびその管理と治療法について詳述.類縁疾患として慢性過敏性肺炎や膠原病肺等についてもとりあげるほか,さまざまな合併症や併存症についても言及している.

目次

  • 1章 疾患概念の定義
    2章 病因・病態論における基礎研究
    3章 診断の進め方
    4章 管理と治療
    5章 特発性間質性肺炎
    6章 類縁疾患の診断と管理
    7章 合併症・併存症の診断と管理
    8章 ガイドラインの活用法と国際的整合性

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1章 疾患概念の定義

P.7 掲載の参考文献
1) 工藤翔二. 特発性肺線維症 (IPF) の歴史と今日の課題. 杉山幸比古編. 特発性肺線維症 (IPF) 改訂版. 医薬ジャーナル社 ; 2013. p.49-61.
2) Hamman L, Rich AR. Acute diffuse interstitial fibrosis of the lungs. Bull Johns Hopkins Hosp 1944 ; 74 : 177-212.
3) Scadding JG. Chronic diffuse interstitial fibrosis of the lungs. Br Med J 1960 ; 1 : 443-50.
4) Liebow AA. New concepts and entities in pulmonary disease. In : Liebow AA, Smith DE, ed. The lungs. Williams & Wilkins ; 1968. p.332-65.
5) Crystal RG, et al. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976 ; 85 : 769-88.
7) Katzenstein AL, et al. Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 1986 ; 10 : 256-67.
8) Katzenstein AL, et al. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994 ; 18 : 136-47.
13) 本間日臣ほか. 肺線維症. 最新医学 1954 ; 9 : 116-29.
14) 杉山幸比古. IPFの歴史と分類上の課題. 呼吸器内科 2011 ; 19 : 503-8.
15) 工藤翔二. わが国の特発性間質性肺炎の歴史と臨床診断基準の第四次改訂. 特発性間質性肺炎の診断と治療の手引き (改訂第2版). 南江堂 ; 2011. p.106-10.
P.11 掲載の参考文献
1) American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002 ; 165 : 277-304.
2) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き. 南江堂 : 2004, p.59-62.
4) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 : 2016, p.1-3.
5) 本間栄. 特発性間質性肺炎 (指定難病 85) 診断・治療指針 (医療従事者向け). 2016. http://www.nanbyou.or.jp/entry/302
P.16 掲載の参考文献
1) 近藤有好ほか. 原因不明のびまん性間質性肺炎. 肺線維症の臨床的研究. 第1報新潟県下の疫学調査と免疫学的研究. 厚生省特定疾患・肺線維症研究班. 昭49年度研究報告書. 1975. p.17.
2) 大野彰二ほか. 臨床調査個人票に基づく特発性間質性肺炎の全国疫学調査. 日呼吸会誌 2007 ; 45 : 759-64.
3) 千葉弘文ほか. 北海道における臨床調査個人票に基づく特発性間質性肺炎の疫学調査. 厚生労働省びまん性肺疾患に関する調査研究班平成20年度報告書. 2009. p.39-46.
8) Kondoh Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993 ; 103 : 1808-12.
9) Ley B, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012 ; 156 : 684-91.

2章 病因・病態論における基礎研究

P.24 掲載の参考文献
3) Borie R, et al. Management of suspected monogenic lung fibrosis in a specialised centre. Eur Respir Rev 2017 ; 26 (144).
8) Blasco MA, et al. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell 1997 ; 91 : 25-34.
13) Bar C, et al. Therapeutic effect of androgen therapy in a mouse model of aplastic anemia produced by short telomeres. Haematologica 2015 ; 100 : 1267-74.
P.35 掲載の参考文献
3) Possmayer F. Physicochemical aspects of pulmonary surfactant. In : Polin RA, eds. Fetal and Neonatal Physiology. WB Saunders ; 1997. p.1259-75.
5) Floros J, Hoover RR. Genetics of the hydrophilic surfactant protein A and D. Biochim et Biophys Acta 1998 ; 1408 : 312-22.
6) Nag K, et al. Correlated atomic force and transmission electron microscopy of nanotubular structures in pulmonsry surfactant. J Struct Biol 1999 ; 126 : 1-15.
7) Schelenz S, et al. Binding of host collectins to the pathogenic yeast Cryptococcus neoformans : human surfactant protein D acts as an agglutinin for acapsular yeast cells. Infect Immun 1995 ; 63 : 3360-6.
8) Benne CA, et al. Surfactant protein A, but not surfactant protein D, is an opsonin for influenza A virus phagocytosis by rat alveolar macrophages. Eur J Immunol 1997 ; 27 : 886-90.
9) Casals C, Gracia-Verdugo I. Molecular and function properties of surfactant protein A. In : Nag K ed. Lung surfactant function and disorder. Tayler & Francis ; 2005. p.59-86.
10) Hoover H, Floors J. Organization of the human SP-A and SP-D loci at 10q22-q23. Physical and radiation hybrid mapping reveal gene order and orientation. Am J Respir Cell Mol Biol 1998 ; 18 : 353-62.
11) Saitoh H, et al. Surfactant protein A2 gene expression by human airway submucosal gland cells. Am J Respir Cell Mol Biol 1998 ; 19 : 202-9.
12) Khubchandani KR, et al. In situ hybridization of SP-A mRNA in adult human conducting airways. Pediatr Pathol Mol Med 2001 ; 20 : 349-66.
13) Nogee L. Genetics of the hydrophobic surfactant proteins. Biochim Biophys Acta 1998 ; 1408 : 323-33.
15) Nogee LM. Alteration in SP-B and SP-C expression in neonatal lung disease. Annu Rev Physiol 2004 ; 66 : 601-23.
17) Weaver TE. Synthesis, processing and secretion of surfactant protein B and C. Biochim Biophys Acta 1998 ; 1408 : 173-9.
18) Weaver TE, Conkright JJ. Function of surfactant protein B and C. Ann Rev Physiol 2001 ; 63 : 555-78.
19) Johnson J, et al. Synthetic surfactant protein analogues. Biol Neonate 1998 ; 74(Suppl 1) : 9-14.
21) Gustafsson M, et al. Amyloid fibril formation by pulmonary surfactant protein C. FEBS Lett 1999 ; 464 : 138-42.
22) Johansson H, et al. The Brichos domain-containing C-terminal part of pro-surfactant protein C binds to an unfolded poly-val transmembrane segment. J Biol Chem 2006 ; 281 : 21032-9.
23) Szyperski T, et al. Pulmonary surfactant-associated polypeptide C in a mixed organic solvent transforms from a monomeric alpha-helical state into insoluble beta-sheet aggregates. Protein Sci 1998 ; 7 : 2533?40.
24) Willander H, et al. BRICHOS domain associated with lung fibrosis, dementia and cancer-a chaperone that prevents amyloid fibril formation? FEBS J 2011 ; 278 : 3893-904.
25) Nogee LM. Surfactant Deficiency Disorders : SP-B and ABC-A3. In : McCormak FX, et al. eds. Molecular Basis of Pulmonary Disease. Humana Press ; 2010. p.247-65.
29) Balch WE, et al. Adapting proteostasis for disease intervention. Science 2008 ; 319 : 916-9.
30) Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest 2002 ; 110 : 1389-98.
31) Meuser B, et al. ERAD : the long road to destruction. Nat Cell Biol 2005 ; 7 : 766-72.
32) Vembar SS, Brodsky JL. One step at a time : endoplasmic reticulum-associated degradation. Nat Rev Mol Cell Biol 2008 ; 9 : 944-57.
35) Johnston JA, et al. Aggresomes : a cellular response to misfolded proteins. J Cell Biol 1998 ; 143 : 1883-98.
39) Marita M, et al. Surfactant protein A2 mutations associated with pulmonary fibrosis lead to protein instability and endoplasmic reticulum stress. J Biol Chem 2010 ; 285 : 22103-13.
40) Wang WJ, et al. Biosynthesis of surfactant protein C (SP-C). Sorting of SP-C proprotein involves homomeric association via a signal anchor domain. J Biol Chem 2002 ; 277 : 19929-37.
41) Brasch F, et al. Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur Respir J 2004 ; 24 : 30-9.
45) Hawkins A, et al. A non-BRICHOS SFTPC mutant (SP-CI73T) linked to interstitial lung disease promotes a late block in macroautophagy disrupting cellular proteostasis and mitophagy. Am J Physiol Lung Cell Mol Physiol 2015 ; 308 : L33-47.
46) Mulugeta S, et al. Lost after translation : insights from pulmonary surfactant for understanding the role of alveolar epithelial dysfunction and cellular quality control in fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol 2015 ; 309 : L 507-25.
P.42 掲載の参考文献
11) Minagawa S, et al. Accelerated epithelial cell senescence in IPF and the inhibitory role of SIRT6 in TGF- β-induced senescence of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2011 ; 300 : L391-401.
P.50 掲載の参考文献
2) Sinha K, et al. Oxidative stress : the mitochondria-dependent and mitochondria-independent pathways of apoptosis. Arch Toxicol 2013 ; 87 : 1157-80.
3) Zhang L, et al. Endoplasmic reticulum stress, a new wrestler, in the pathogenesis of idiopathic pulmonary fibrosis. Am J Transl Res 2017 ; 9 : 722-35.
5) Shimizu S, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004 ; 6 : 1221-8.
P.55 掲載の参考文献
2) Lee MG, Lee YH. A meta-analysis examining the association between the MUC5B rs35705950 T/G polymorphism and susceptibility to idiopathic pulmonary fibrosis. Inflamm Res 2015 ; 64 : 463-70.
9) Oldham JM, et al. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2015 ; 192 : 1475-82.
10) Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 : 366 : 1968-77.
P.60 掲載の参考文献
1) Foster DA, Toschi A. Targeting mTOR with rapamycin : one dose does not fit all. Cell Cycle 2009 ; 8 : 1026-9.
2) Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009 ; 122 : 3589-94.
4) Chang W, et al. A critical role for the mTORC2 pathway in lung fibrosis. PLoS One 2014 ; 9 : e106155.
10) D'Amato L, et al. ARHGEF3 controls HDACi-induced differentiation via RhoA-dependent pathways in acute myeloid leukemias. Epigenetics 2015 ; 10 : 6-18.
P.65 掲載の参考文献
7) Nallet-Staub F, et al. Cell density sensing alters TGF-β signaling in a cell-type-specific manner, independent from Hippo pathway activation. Dev Cell 2015 ; 32 : 640-51.

3章 診断の進め方

P.73 掲載の参考文献
1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016.
4) 坂東政司. びまん性肺疾患診断へのアプローチ. 内科 2016 ; 117 : 179-83.
6) Richeldi L, et al. Design of the INPULSIS(TM) trials : two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med 2014 ; 108 : 1023-30.
9) Bando M, et al. A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan. Respir Investig 2015 ; 53 : 51-9.
P.78 掲載の参考文献
2) Myers KA, Farquhar DR. The rational clinical examination. Does this patient have clubbing? JAMA 2001 ; 286 : 341-7.
4) 池田啓. 関節リウマチの鑑別診断に有用な症状・身体所見. 日内会誌 2014 ; 103 : 2407-12.
8) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第2版. 南江堂 ; 2011.
9) Kondoh Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993 ; 103 : 1808-12.4
P.86 掲載の参考文献
1) Watanabe K. Pleuroparenchymal Fibroelastosis : Its Clinical Characteristics. Curr Respir Med Rev 2013 ; 9 : 229-37.
5) Setern EJ, et al. CT mosaic pattern of lung attenuation : etiologies and terminology. J Thorac Imaging 1995 ; 10 : 294-7.
P.95 掲載の参考文献
1) Fishman AP. Assessment of Pulmonary Function. McGraw-Hill ; 1980. p.221.
2) ジョンBウエスト著, 堀江孝至, 桑平一郎訳. ウエスト呼吸生理学入門疾患肺編. メディカル・サイエンス・インターナショナル ; 2018.
3) West JB, Wagner PD. Ventilation-perfusion relationship. In : Crystal RG, et al, ed. The Lung Scientific Foundations, 2nd ed. Raven Press ; 1997. p.1693-709.
14) Ley B, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012 ; 156 : 684-91.
15) 千葉弘文, 高橋弘毅. 診断と治療のABC108特発性肺線維症とその周辺疾患. 吾妻安良太企画. 最新医学社 ; 2015. p.23-30.
P.100 掲載の参考文献
1) 大塚満雄ほか. びまん性肺疾患の分類と診断-血清診断 : 疾患活動性マーカー. 内科 2016 ; 117 : 211-4.
2) Ishii H, et al. High serum concentrations of surfactant protein A in usual interstitial pneumonia compared with non-specific interstitial pneumonia. Thorax 2003 ; 58 : 52-7.
10) Yanaba K, et al. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004 ; 31 : 1112-20.
11) Bandoh S, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis. Ann Rheum Dis 2000 ; 59 : 257-62.
13) 千葉弘文ほか. 血清中にSP-Dに対する自己抗体をみとめたDermatomyositisの一例. 日本肺サーファクタント・界面医学会雑誌 2007 ; 38 : 52-4.
15) Takahashi H, et al. Diagnostic significance of surfactant proteins A and D in sera from patients with radiation pneumonitis. Eur Respir J 2001 ; 17 : 481-7.
16) Ohnishi H, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. Thorax 2003 ; 58 : 872-5.
17) 四十坊典晴, 山口哲夫. サルコイドーシス診断基準における特徴的な検査項目の検討. 厚生労働省科学研究費補助金難治性疾患克服研究事業びまん性肺疾患に関する調査研究班. びまん性肺疾患に関する調査研究 : 平成25年度研究報告書. 2014 ; p.359-62.
18) Onishi A, et al. Diagnostic accuracy of serum 1, 3-β-D-glucan for pneumocystis jiroveci pneumonia, invasive candidiasis, and invasive aspergillosis : systematic review and meta-analysis. J Clin Microbiol 2012 ; 50 : 7-15.
P.105 掲載の参考文献
1) Reynolds HY, Newball HH. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med 1974 ; 84 : 559-73.
2) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016.
4) Hiwatari N, et al. Bronchoalveolar lavage as a possible cause of acute exacerbation in idiopathic pulmonary fibrosis patients. Tohoku J Exp Med 1994 ; 174 : 379-86.
5) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.Am J Respir Crit Care Med 2002 ; 165 : 277-304.
6) Ohshimo S, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009 ; 179 : 1043-7.
8) Antonelli M, et al. Noninvasive positive-pressure ventilation vs. conventional oxygen supplementation in hypoxemic patients undergoing diagnostic bronchoscopy. Chest 2002 ; 121 : 1149-54.
9) 香川友祐ほか. びまん性肺疾患におけるネーザルハイフローシステム使用下気管支鏡検査の有用性の検討. 気管支学 2016 ; 38 : 266-71.
P.112 掲載の参考文献
2) Utz JP, et al. High short-term mortality following lung biopsy for usual interstitial pneumonia. Eur Respir J 2001 ; 17 : 175-9.
6) Curley FJ, et al. Transbronchial lung biopsy : can specimen quality be predicted at the time of biopsy? Chest 1998 ; 113 : 1037-41.
7) Du Rand IA, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults : accredited by NICE. Thorax 2013 ; 68 Suppl 1 : i1-i44.
8) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第2版. 南江堂 ; 2011. p.17.
9) American Thoracic Society ; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002 ; 165 : 277-304.
13) Sheth JS, et al. Utility of Transbronchial vs Surgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease. Chest 2017 ; 151 : 389-99.
P.118 掲載の参考文献
5) 奥寺康司. 肺疾患の新たな診断手技としてのクライオバイオプシー-病理診断の実際. 呼吸臨床 2017 ; 1 : e00004.
8) Pajares V, et al. Diagnostic yield of transbronchial cryobiopsy in interstitial lung disease : a randomized trial. Respirology 2014 ; 19 : 900-6.
11) Ravaglia C, et al. Safety and Diagnostic Yield of Transbronchial Lung Cryobiopsy in Diffuse Parenchymal Lung Diseases : A Comparative Study versus Video-Assisted Thoracoscopic Lung Biopsy and a Systematic Review of the Literature. Respiration 2016 ; 91 : 215-27.
13) Hetzel J, et al. Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases : Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure. Respiration. 2018 ; 95 : 188-200.
P.126 掲載の参考文献

4章 管理と治療

P.133 掲載の参考文献
3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 管理総論. 特発性間質性肺炎診断と治療の手引き, 改定第3版. 南江堂 ; 2016. p.111-2.
P.138 掲載の参考文献
2) Martinez TY, et al. Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. Chest 2000 ; 117 : 1627-32.
3) Tomioka H, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis-crosssectional and longitudinal study. Intern Med 2007 ; 46 : 1533-42.
4) Swigris JJ, et al. Pulmonary rehabilitation in idiopathic pulmonary fibrosis : a call for continued investigation. Respir Med 2008 ; 102 : 1675-80.
6) Kozu R, et al. Difference in response to pulmonary rehabilitation in idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respiration 2011 ; 81 : 196-205.
7) Wallaert B, et al. Physical activity in daily life of patients with fibrotic idiopathic interstitial pneumonia. Chest 2013 ; 144 : 1652-8.
8) Collard HR, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med 2016 ; 194 : 265-75.
10) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016. p.113-4.
11) 冨岡洋海. 間質性肺炎患者への生活指導. 呼吸器ケア 2009 ; 7 : 206-10.
18) Sato S, et al. Possible maximal change in the SF-36 of outpatients with chronic obstructive pulmonary disease and asthma. J Asthma 2004 ; 41 : 355-65.
P.148 掲載の参考文献
2) 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班特発性肺疾患の治療ガイドライン作成委員会編. 特発性肺線維症の治療ガイドライン 2017. 南江堂 ; 2017.
4) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改定第3版. 南江堂 ; 2016, p.116-22.
6) Raghu G, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012 ; 366 : 1968-77.
23) Meyer A, et al. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994 ; 7 : 431-6.
24) Behr J, et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997 ; 156 : 1897-901.
P.156 掲載の参考文献
1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎の診断と治療の手引き, 改訂第3版. 南江堂 ; 2016.
8) 厚生労働科学研究費助成金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班特発性肺線維症の治療ガイドライン作成委員会編. 特発性肺線維症の治療ガイドライン 2017. 南江堂 ; 2017.
11) Navaratnam V, et al. Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis : a population-based case-control study. Thorax 2014 ; 69 : 207-15.
15) Panos RJ, et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis : causes and assessment. Am J Med 1990 ; 88 : 396-404.
16) Wiggins J, et al. Combined cryptogenic fibrosing alveolitis and emphysema : the value of high resolution computed tomography in assessment. Respir Med 1990 ; 84 : 365-9.
17) 本間行彦ほか. 特発性間質性肺炎 (IIP) の臨床的診断基準-第3次改訂案. 厚生省特定疾患びまん性肺疾患調査研究班, 平成3年度研究報告書 : 20, 1992.
19) Papiris SA, et al. Combined pulmonary fibrosis and emphysema. Expert Rev Respir Med 2013 ; 7 : 19-31.
30) Abolnik I, et al. Spontaneous pneumomediastinum. A report of 25 cases. Chest 1991 ; 100 : 93-5.
31) 井上幸久ほか. 続発性気胸を合併した間質性肺炎の臨床的検討. 日呼吸会誌 2010 ; 48 : 724-8.
34) Aihara K, et al. Efficacy of blood-patch pleurodesis for secondary spontaneous pneumothorax in interstitial lung disease. Intern Med 2011 ; 50 : 1157-62.
35) Tsukioka T, et al. Pleurodesis with a 50% glucose solution in patients with spontaneous pneumothorax in whom an operation is contraindicated. Ann Thorac Cardiovasc Surg 2013 ; 19 : 358-63.
36) 藤野孝介ほか. 50%ブドウ糖液を使用した胸膜癒着術の有効性. 日呼外会誌 2013 ; 27 : 670-4.
43) Hernandez-Rodriguez NA, et al. Role of thrombin in pulmonary fibrosis. Lancet 1995 ; 346 : 1071-3.
49) Mermigkis C, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath 2015 ; 19 : 385-91.
P.163 掲載の参考文献
2) Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981 ; 1 : 681-6.
3) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease : a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980 ; 93 : 391-8.
7) 日本呼吸ケア・リハビリテーション学会酸素療法マニュアル作成委員会, 日本呼吸器学会肺生理専門委員会編. 酸素療法マニュアル. メディカルレビュー社 ; 2017.
14) Arizono S, et al. Benefits of supplemental oxygen on exercise capacity in IPF patients with exerciseinduced hypoxemia. Eur Respir J 2015 ; 46 : OA4971.
21) Jacobs SS, et al. Patient Perceptions of the Adequacy of Supplemental Oxygen Therapy. Results of the American Thoracic Society Nursing Assembly Oxygen Working Group Survey. Ann Am Thorac Soc 2018 ; 15 : 24-32.
P.168 掲載の参考文献
2) 西山理ほか. 特発性肺線維症に対する多面的評価と呼吸リハビリテーション. 日本呼吸ケア・リハビリテーション学会誌 2011 ; 21 : 232-6.
5) Mendoza L, et al. Quadriceps strength and endurance in fibrotic idiopathic interstitial pneumonia. Respirology 2014 ; 19 : 138-43.
13) National Clinical Guideline Centre (UK). Diagnosis and Management of Suspected Idiopathic Pulmonary Fibrosis : Idiopathic Pulmonary Fibrosis. NICE Clinical Guidelines, No.163. London : Royal College of Physicians (UK) ; 2013.
P.173 掲載の参考文献

5章 特発性間質性肺炎

P.184 掲載の参考文献
1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016.
9) Ley B, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012 ; 156 : 684-91.
10) Meyer KC, et al. An official American Thoracic Society clinical practice guideline : the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012 ; 185 : 1004-14.
19) 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班特発性肺線維症の治療ガイドライン作成委員会編. 特発性肺線維症の治療ガイドライン 2017. 南江堂 ; 2017.
20) Collard HR, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016 ; 194 : 265-75.
P.192 掲載の参考文献
1) Katzenstein AL, et al. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol 1994 ; 18 : 136-47.
4) Bando M, et al. A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan. Respir Investig 2015 ; 53 : 51-9.
6) Kim DS. Idiopathic nonspecific interstitial pneumonia : an unrecognized autoimmune disease? Am J Respir Crit Care Med 2007 ; 176 : 632-3.
8) Travis WD, et al. Idiopathic nonspecific interstitial pneumonia : prognostic significance of cellular and fibrosing pattern : survival comparison with usual interstitial pneumonia and desquamative interstitial pneumonia. Am J Surg Pathol 2000 ; 24 : 19-33.
16) Akira M, et al. Non-specific interstitial pneumonia : findings on sequential CT scans of nine patients. Thorax 2000 ; 55 : 854-9.
17) Silva CI, et al. Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis : changes in patterns and distribution disease over time. Radiology 2008 ; 247 : 251-9.
21) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016.
P.196 掲載の参考文献
1) Natsuizaka M, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethic differences. Am J Respir Crit Care Med 2014 ; 190 : 773-9.
3) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016. p.72.
5) Collrad HR, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016 ; 194 : 265-75.
8) Schupp JC, et al. Macrophage activation in acute exacerbations of idiopathic pulmonary fibrosis. PLoS One 2015 ; 10 : e0116775.
20) Kondoh Y, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010 ; 27 : 103-10.
P.203 掲載の参考文献
1) Cordier JF, et al. Idiopathic bronchiolitis obliterans organizing pneumonia. Definition of characteristic clinical profiles in a series of 16 patients. Chest 1989 ; 96 : 999-1004.
2) American Thoracic Society ; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002 ; 165 : 277-304.
5) Schlesinger C, Koss MN. The organizing pneumonias : an update and review. Curr Opin Pulm Med 2005 ; 11 : 422-30.
9) Miao L, et al. Lesion with morphologic feature of organizing pneumonia (OP) in CT-guided lung biopsy samples for diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP) : a retrospective study of 134 cases in a single center. J Thorac Dis 2014 ; 6 : 1251-60.
11) Lazor R, et al. Cryptogenic organizing pneumonia. Characteristics of relapses in a series of 48 patients. The Groupe d'Etudes et de Recherche sur les Maladles "Orphelines" Pulmonaires (GERM "O" P). Am J Respir Crit Care Med 2000 ; 162 : 571-7.
12) Nizami IY, et al. Idiopathic bronchiolitis obliterans with organizing pneumonia. An acute and lifethreatening syndrome. Chest 1995 ; 108 : 271-7.
P.208 掲載の参考文献
1) Katzenstein AL, et al. Acute interstitial pneumonia. A clinicopathologic, ultra-structural, and cell kinetic study. Am J Surg Pathol 1986 ; 10 : 256-67.
2) 日本呼吸器学会びまん性肺疾患および診断・治療ガイドライン作成委員会編. 急性間質性肺炎 (AIP). 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016. p.83-7.
7) 日本呼吸器学会NPPVガイドライン作成委員会編. 間質性肺炎. NPPV (非侵襲的陽圧換気療法) ガイドライン. 南江堂 ; 2015. p.72-6.
9) Gannon WD, et al. Outcomes and Mortality Prediction Model of Critically Ill Adults With Acute Respiratory Failure and Interstitial Lung Disease. Chest 2018 ; pii : S0012-3692 (18) 30078-3.
11) Goncalves-Venade G, et al. Extracorporeal Membrane Oxygenation for Refractory Severe Respiratory Failure in Acute Interstitial Pneumonia. Artif Organs 2018. doi : 10.1111/aor.13075.
P.213 掲載の参考文献
1) Kumar A, et al. Current Concepts in Pathogenesis, Diagnosis, and Management of Smoking-Related Interstitial Lung Diseases. Chest 2017. doi : 10.1016/j.chest. 2017. 11. 023.
5) Yousem SA. Respiratory bronchiolitis-associated interstitial lung disease with fibrosis is a lesion distinct from fibrotic nonspecific interstitial pneumonia : a proposal. Mod Pathol 2006 ; 19 : 1474-9.
6) Kawabata Y, et al. Smoking-related changes in the background lung of specimens resected for lung cancer : a semiquantitative study with correlation to postoperative course. Histopathology 2008 ; 53 : 707-14.
7) Katzenstein A-LA, et al. Clinically occult interstitial fibrosis in smokers : classification and significance of a surprisingly common finding in lobectomy specimens. Hum Pathol 2010 ; 41 : 316-25.
9) Marten K, et al. Non-specific interstitial pneumonia in cigarette smokers : a CT study. Eur Radiol 2009 ; 19 : 1679-85.
P.217 掲載の参考文献
1) Liebow AA. The interstitial pneumonias. In : Simon M, et al, editors. Frontiers of Pulmonary Radiology. 1st edition. Grune & Stratton ; 1969. p.102-41.
2) Liebow AA, Carrington CB. Diffuse pulmonary lymphoreticular infiltrations associated with dysproteinemia. Med Clin North Am 1973 ; 57 : 809-43.
3) Kradin RL, et al. Immunoblastic lymphoma arising in chronic lymphoid hyperplasia of the pulmonary interstitium. Cancer 1982 ; 50 : 1339-43.
4) American Thoracic Society ; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002 ; 165 : 277-304.
6) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. リンパ球性間質性肺炎 (LIP). 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016. p.95-8.
7) Strimlan CV, et al. Lymphocytic interstitial pneumonitis. Review of 13 cases. Ann Intern Med 1978 ; 88 : 616-21.
8) Koss MN, et al. Lymphoid interstitial pneumonia : clinicopathological and immunopathological find ings in 18 cases. Pathology 1987 ; 19 : 178-85.
11) 上甲剛. ATS-ERS02診断基準によるリンパ球性間質性肺炎 (Lymphocytic interstitial pneumonia (LIP)) のCT所見. びまん性肺疾患に関する調査研究班 : 平成21年度研究報告書 : 厚生労働科学研究費補助金難治性疾患克服研究事業. 2010. p.147-50.
14) Kaan PM, et al. Expression of bcl-2 and Epstein-Barr virus LMP1 in lymphocytic interstitial pneumonia. Thorax 1997 ; 52 : 12-6.
P.224 掲載の参考文献
1) 網谷良一ほか. 特発性上葉限局型肺線維症. 呼吸 1992 ; 11 : 693-9.
3) Travis WD, et al. An official American Thoracic Society/European Respiratory Society statement : Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Resipr Crit Care Med 2013 ; 188 : 733-48.
9) Weber B, et al. Pulmonary function in asymptomatic adolescents with idiopathic scoliosis. Am Rev Respir Dis 1975 ; 11 : 389-97.
P.229 掲載の参考文献
4) Beasley MB. The pathologist's approach to acute lung injury. Arch Pathol Lab Med 2010 ; 134 : 719-27.
6) Tazelaar HD, et al. Acute eosinopilic pneumonia : histopathologic findings in nine patients. Am J Respir Crit Care Med 1997 ; 155 : 296-302.
14) Churg A, et al. Airway-centered interstitial fibrosis : a distinct form of aggressive diffuse lung disease. Am J Surg Pathol 2004 ; 28 : 62-8.
15) Fukuoka J, et al. Peribronchiolar metaplasia : a common histologic lesion in diffuse lung disease and a rare cause of interstitial lung disease : clinicopathologic features of 15 cases. Am J Surg Pathol 2005 ; 29 : 948-54.
17) Kuranishi LY, et al. Airway-centered interstitial fibrosis : etiology, clinical findings and prognosis. Respir Res 2015 ; 16 : 55.
P.233 掲載の参考文献
1) 長和俊. 遺伝性間質性肺疾患. 周産期医学 2016 ; 46 : 1365-8.
4) 小杉雄二郎ほか. 肺サーファクタント蛋白C遺伝子異常による先天性肺胞蛋白症の1例. 日本周産期・新生児医学会雑誌 2013 ; 49 : 1346-51.
10) Ito Y, et al. A late presenter and long-term survivor of alveolar capillary dysplasia with misalignment of the pulmonary veins. Eur J Pediatr 2015 ; 174 : 1123-6.
12) Hadchouel A, et al. Biallelic Mutations of Methionyl-tRNA Synthetase Cause a Specific Type of Pulmonary Alveolar Proteinosis Prevalent on Reunion Island. Am J Hum Genet 2015 ; 96 : 826-31.
P.238 掲載の参考文献
1) American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002 ; 165 : 277-304.
7) Raghu G, Collard HR, Egan JJ, et al. ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement : idiopathic pulmonary fibrosis : evidencebased guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011 ; 183 : 788-824.

6章 類縁疾患の診断と管理

P.247 掲載の参考文献
1) Yoshizawa Y, et al. Chronic hypersensitivity pneumonitis in Japan : a nationwide epidemiologic survey. J Allergy Clin Immunol 1999 ; 103 : 315-20.
2) Ohtani Y, et sl. Clinical features of recurrent and insidious chronic bird fancier's lung. Ann Allergy Asthma Immunol 2003 ; 90 : 604-10.
3) 宮崎泰成, 稲瀬直彦. 過敏性肺炎の病態と治療の最前線. 日本内科学会雑誌 2017 ; 106 : 1212-20.
9) Perez-Padilla R, et al. Mortality in Mexican patients with chronic pigeon breeder's lung compared with those with usual interstitial pneumonia. Am Rev Respir Dis 1993 ; 148 : 49-53.
10) 米田良蔵. 過敏性肺炎診断の手引きと診断基準. 厚生省特定疾患びまん性肺疾患調査研究班平成2年度報告書. 1990 : 13-5.
11) Fournier E, et al. Early neutrophil alveolitis after antigen inhalation in hypersensitivity pneumonitis. Chest 1985 ; 88 : 563-6.
12) Costabel U. The alveolitis of hypersensitivity pneumonitis. Eur Respir J 1988 ; 1 : 5-9.
13) Nielsen CH, Leslie RG. Complement's participation in acquired immunity. J Leukoc Biol 2002 ; 72 : 249-61.
15) Ishizuka M, et al. Interleukin-17A and Neutrophils in a Murine Model of Bird-Related Hypersensitivity Pneumonitis. PLoS One 2015 ; 10 : e0137978.
16) Suga M, et al. Mechanisms accounting for granulomatous responses in hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis 1997 ; 14 : 131-8.
18) Simonian PL, et al. Th17-polarized immune response in a murine model of hypersensitivity pneumonitis and lung fibrosis. J Immunol 2009 ; 182 : 657-65.
20) Yoshizawa Y, et al. A follow-up study of pulmonary function tests, bronchoalveolar lavage cells, and humoral and cellular immunity in bird fancier's lung. J Allergy Clin Immunol 1995 ; 96 : 122-9.
21) Murayama J, et al. Lung fibrosis in hypersensitivity pneumonitis. Association with CD4+ but not CD8+ cell dominant alveolitis and insidious onset. Chest 1993 ; 104 : 38-43.
24) Belperio J, et al. The role of the Th2 CC Chemokine Ligand CCL17 in pulmonary fibrosis. J Immunol 2004 ; 173 : 4692-8.
29) Ohtani Y, et al. Chronic bird fancier's lung : histopathological and clinical correlation. An application of the 2002 ATS/ERS consensus classification of the idiopathic interstitial pneumonias. Thorax 2005 ; 60 : 665-71.
P.256 掲載の参考文献
1) Aletaha D, et al. 2010 Rheumatoid arthritis classiffication criteria : an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010 ; 62 : 2569-81.
4) Bongartz T, et al. Incidence and mortality of interstitial lung disease in rheumatoid arthritis : a population-based study. Arthrits Rheum 2010 ; 62 : 1583-91.
6) 槇野茂樹. 膠原病の間質性肺炎. 臨床リウマチ 2012 ; 24 : 165-71.
10) 荒武弘一朗ほか. 間質性肺炎の急性増悪を認めた慢性関節リウマチの1剖検例. 日本臨床免疫学会会誌 1998 ; 21 : 129-36.
11) Zamora-Legoff JA, et al. Progressive Decline of Lung Function in Rheumatoid Arthritis-Associated Interstitial Lung Disease. Arthrits Rheum 2017 ; 69 : 542-9.
12) 久保恵嗣ほか. 薬剤性肺障害の評価, 治療についてのガイドライン. 日本呼吸器学会雑誌 2006 ; 44 : 239-87.
14) Conway R, et al. Methotrexate and lung disease in rheumatoid arthritis : a meta-analysis of randomized controlled trials. Arthritis Rheum 2014 ; 66 : 803-12.
P.264 掲載の参考文献
2) van den Hoogan F, et al. 2013 classification criteria for systemic sclerosis : an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013 ; 65 : 2737-47.
3) Man A, et al. Changes in forced vital capacity over time in systemic sclerosis : application of groupbased trajectory modeling. Rheumatology (Oxford) 2015 ; 54 : 1464-71.
6) Kuwana M, et al. Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease. J Rheumatol 2016 ; 43 : 1825-31.
10) Tashkin DP, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II) : a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016 ; 4 : 708-19.
13) Sullivan KM, et al. Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. N Engl J Med 2018 ; 378 : 35-47.
15) Khanna D, et al. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease : the LOTUSS Trial. J Rheumatol 2016 ; 43 : 1672-9.
P.273 掲載の参考文献
1) Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991 ; 24 : 959-66.
2) Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sine myositis) as a distinctive subset within the idiopathic inflammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol 2002 ; 46 : 626-36.
3) 難治性疾患政策研究事業自己免疫疾患に関する調査研究班多発性筋炎皮膚筋炎分科会編. 多発性筋炎・皮膚筋炎治療ガイドライン. 診断と治療社 ; 2015. p. xi-xv.
4) Bottai M, et al. EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups : a methodology report. RMD Open 2017 ; 14 ; 3 (2) : e000507.
9) Sato S, et al. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies. PLoS One 2016 ; 26 : 11 (4) : e0154285.
P.279 掲載の参考文献
5) Nakamura Y, et al. Nonspecific interstitial pneumonia in collagen vascular diseases : comparison of the clinical characteristics and prognostic significance with usual interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2003 ; 20 : 235-41.
14) Mosca M, et al. Undifferentiated connective tissue diseases (UCTD) : a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999 ; 17 : 615-20.
19) Fischer A, et al. Connective tissue disease-associated interstitial lung disease : a call for clarification. Chest 2010 ; 138 : 251-6.
31) Ahmad K, et al. Interstitial pneumonia with autoimmune features : Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. Respir Med 2017 ; 123 : 56-62.
P.287 掲載の参考文献
1) 有村義宏ほか編. ANCA関連血管炎診療ガイドライン 2017. 厚生労働科学研究費補助金厚生労働省難治性疾患克服研究事業. 2017.
11) 白木晶ほか. 間質性肺炎におけるmyeloperoxidase antineutrophil cytoplasmic antibodyの陽性率と予後の検討. 日呼吸会誌 2007 ; 45 : 921-6.
12) 小倉高志, 蛇澤晶. ANCA関連間質性肺炎. 日本胸部臨床 2013 ; 72 : S248-55.
13) Homma S, et al. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibodyassociated vasculitides. Respirology 2004 ; 9 : 190-6.
18) Suzuki A, et al. Clinical characteristics in pulmonary limited MPA. Jpn Thorac Dis 2012 ; 1 : 252 (abstact).
21) 蛇澤晶ほか. MPO-ANCA陽性症例における慢性間質性肺炎の病理. 日胸 2008 ; 67 : 210-9.
P.294 掲載の参考文献
1) 日本呼吸器学会薬剤性肺障害の診断・治療の手引き作成委員会編. 薬剤性肺障害の診断・治療の手引き. メディカルレビュー社 ; 2012. p.12-74.
2) Schwartz MI, King TE. Interstitial Lung Disease, 5th edition. In : Schwartz MI editors. PMPHUSA ; 2010. p.637-88.
3) Thomeer M, et al ; VRGT Working Group on Interstitial Lung Diseases. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg 2001 ; 56 : 163-72.
4) Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. JMAJ 2007 ; 50 : 405-11.
5) Handa T, et al. Epidemiology and Risk Factors of Drug-Induced Lung Disease. Drug-Induced Lung Injury. Hanaoka M, et al. editors. Springer ; 2018.
6) 独立行政法人医薬品医療機器総合機構 (Pharmaceutical and Medical Device Agency) ホームページ. http://www.pmda.go.jp/.
9) Shiihara J, et al. MUC4 variants in patients with EGFR-TKI-induced interstitial lung disease and its detection assay. The 55th annual meeting of Japan lung cancer society, Kyoto, 2014.
14) Gettinger SN, et al. Pneumonitis in non-small cell lung cancer (NSCLC) patients treated with programmed death 1 (PD1) axis inhibitors. J Clin Oncol 2016 (suppl ; abstr 9030)
16) Delaunay M, et al. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 2017 Aug 10 ; 50 (2).
18) Alarcon GS, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997 ; 127 : 356-64.
19) Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum 2004 ; 50 : 1370-82.
22) Dusman RE, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990 ; 82 : 51-9.
23) Yamada Y, et al. Incidence and predictors of pulmonary toxicity in Japanese patients receiving lowdose amiodarone. Circ J 2007 ; 71 : 1610-6.
P.300 掲載の参考文献
1) Wiggins J, et al. Combined cryptogenic fibrosing alveolitis and emphysema : the value of high resolution computed tomography in assessment. Respir Med 1990 ; 84 : 365-9.
2) 本間行彦ほか. 特発性間質性肺炎 (IIP) の臨床的診断基準第3次改定案. 厚生省特定疾患びまん性肺疾患調査研究班平成3年度報告書. 1992. p.20-32.

7章 合併症・併存症の診断と管理

P.306 掲載の参考文献
4) Natsuizaka M, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 2014 ; 90 : 773-9.
6) Ley B, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012 ; 156 : 684-91.
10) West JB. Structure and Function. In : Respiratory Physiology - the essentials. 5th ed. Williams & Wilkins ; 1995. p.1-10.
11) 禁煙推進委員会ホームページ. 喫煙の健康影響・禁煙の効果. http://www.j-circ.or.jp/kinen/iryokankei/eikyo.htm
P.314 掲載の参考文献
1) 千葉弘文ほか. 北海道における臨床調査個人票に基づく特発性間質性肺炎の疫学調査 (北海道 study). 厚生省特定疾患「びまん性肺疾患」調査研究班平成21年度研究報告書. 2010. p.59-67.
2) Kondoh Y, et al. Acute exacerbation in idiopathic pulmonary fibrosis. Analysis of clinical and pathologic findings in three cases. Chest 1993 ; 103 : 1808-12.
3) Collard HR, et al. Idiopathic Pulmonary Fibrosis Clinical Research Netwprk Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007 ; 176 : 636-43.
4) 佐藤篤彦. 特発性間質性肺炎と関連疾患分科会総括報告. 厚生省特定疾患びまん性肺疾患調査研究班平成6年度研究報告書. 1995. p.911.
5) 谷口博之, 近藤康博. 特発性肺線維症の急性増悪の新しい診断基準について. 厚生労働省特定疾患びまん性肺疾患調査研究班, 平成15年度研究報告書. 2004. p.1149.
6) Collard HR, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016 ; 194 : 265-75.
7) Kondoh Y, et al. Risk factors of acute exacerbation of idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2010 ; 27 : 103-10.
14) Sato T, et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg 2015 ; 63 : 164-72.
20) Schwarz MI, Albert RK. "Imitators" of the ARDS : implications for diagnosis and treatment. Chest 2004 ; 125 : 1530-5.
25) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016.
26) 厚生労働科学研究費補助金難治性疾患政策研究事業びまん性肺疾患に関する調査研究班特発性肺線維症の治療ガイドライン作成委員会編. 特発性肺線維症の治療ガイドライン 2017. 南江堂 ; 2017.
28) Homma S, et al. Cyclosporin treatment in steroid-resistant and acutely exacerbated interstitial pneumonia. Intern Med 2005 ; 44 : 1144-50.
29) Horita N, et al. Tacrolimus and steroid treatment for acute exacerbation of idiopathic pulmonary fibrosis. Intern Med 2011 ; 50 : 189-95.
30) Novelli L, et al. Corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis : a single center experience and literature review. Sarcoidosis Vasc Diffuse Lung Dis 2016 ; 33 : 385-91.
31) 川村宏大ほか. 間質性肺炎に対する少量ステロイド併用シクロスポリン治療中の悪性腫瘍発症例の検討. 日呼吸会誌 2010 ; 48 : 261-6.
37) Abe S, et al. Polymyxin B-immobilized fiber column (PMX) treatment for idiopathic pulmonary fibrosis with acute exacerbation : a multicenter retrospective analysis. Intern Med 2012 ; 51 ; 1487-91.
39) van Manen MJG, et al. Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. Eur Res J 2017 ; 50 : 1701157.
P.320 掲載の参考文献
1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016. p.45-60.
5) Enomoto T, et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 2003 ; 123 : 2007-11.
6) 須賀達夫ほか. 糖尿病を合併した特発性問質性肺炎症例の検討. 日胸疾会誌 1994 ; 32 : 1131-5.
8) Figueroa MCG, et al. Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respir Med 2010 ; 104 : 305-9.
10) 松原貴規, 原文男. ヒト糖尿病における肺機能異常および肺末梢組織病変に関する研究. 日医大誌 1991 ; 58 : 528-36.
11) Yung J, et al. Pulmonary fibrosis : a possible diabetic complication. Diabetes Metab Res Rev 2011 ; 27 : 311-7.
12) Matsuse T, et al. Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis. J Clin Pathol 1998 ; 51 : 515-9.
13) Usuki J, et al. Influence of hyperglycemia to the severity of pulmonary fibrosis. Chest 2001 ; 120 : 71S.
P.324 掲載の参考文献
7) Collard HR, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med 2016 ; 194 : 265-75.
8) Maini R, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis 2013 ; 19 : 386-92.
12) Namkoong H, et al. Epidemiology of Pulmonary Nontuberculous Mycobacterial Disease, Japan (1). Emerg Infect Dis 2016 ; 22 : 1116-7.
13) Kurosaki F, et al. Clinical features of pulmonary aspergillosis associated with interstitial pneumonia. Intern Med 2014 ; 53 : 1299-306.
14) 日本医真菌学会アスペルギルス症の診断・治療ガイドライン作成委員会編. アスペルギルス症の診断・治療ガイドライン. 日本医真菌学会 ; 2015.
P.329 掲載の参考文献
1) 日本消化器病学会. 胃食道逆流症 (GERD) 診療ガイドライン 2015, 改訂第2版. 南江堂 ; 2015.
6) Tsugeno H, et al. A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. Scand J Gastroenterol 2003 ; 38 : 456-61.
9) Nakase H, et al. Relationship between asthma and gastro-oesophageal reflux : significance of endoscopic grade of reflux oesophagitis in adult asthmatics. J Gastroenterol Hepatol 1999 ; 14 : 715-22.
14) Bandeira CD, et al. Prevalence of gastroesophageal reflux disease in patients with idiopathic pulmonary fibrosis. J Bras Pneumol 2009 ; 35 : 1182.
16) Stein MR, et al. Gastroesophageal Reflux Disease & Airway Disease. Lung Biology in Health & Disease, Book 129. CRC Press ; 1999.
17) Mays EE, et al. Pulmonary fibrosis associated with tracheobronchial aspiration. A study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology. Chest 1976 ; 69 : 512-5.
19) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第2版. 南江堂 ; 2011.
22) Lee JS, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis : an analysis of data from three randomized controlled traials. Lancet Respir Med 2013 ; 1 : 369-76.
25) Raghu G, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012 ; 366 : 1968-77.
31) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会編. 特発性間質性肺炎診断と治療の手引き, 改訂第3版. 南江堂 ; 2016.
P.338 掲載の参考文献
3) 守尾嘉晃. IPFに合併する二次性肺高血圧症の管理. 呼吸器内科 2015 ; 28 : 358-64.
20) Hurdman J, et al. ASPIRE registry : assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012 ; 39 : 945-55.
33) Corporation B. Bayer Terminates Phase II Study with Riociguat in Patients with Pulmonary Hypertension Associated with Idiopathic Interstitial Pneumonias. 2016. https://www.prnewswire.com/news-releases/bayer-terminates-phase-ii-study-with-riociguat-in-patients-with-pulmonary-hypertension-associated-with-idiopathic-interstitial-pneumonias-300267616.html (date last accessed : 2018.6.5.)
36) Galie N, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension : The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by : Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016 ; 37 : 67-119.
P.345 掲載の参考文献
2) Minegishi Y, et al. Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern Med 2009 ; 48 : 665-72.
4) Miura Y, Azuma A. Pirfenidone : an orphan drug for treating idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs 2015 ; 3 : 587-97.
8) Fujiwara A, et al. Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer. Lung Cancer 2017 ; 106 : 8-16.
11) van Zandwijk N. N-acetylcysteine for lung cancer prevention. Chest 1995 ; 107 : 1437-41.
P.350 掲載の参考文献
1) 日本呼吸器学会腫瘍学術部会・びまん性肺疾患学術部会. 間質性肺炎合併肺癌の臨床像. 間質性肺炎合併肺癌に関するステートメント. 南江堂 ; 2017. p.19-21.
2) 宮本篤ほか. 特発性間質性肺炎合併肺癌患者の内科治療に関する後ろ向き調査. びまん性肺疾患に関する調査研究班平成29年度研究報告書 part 1. 2018. p.39-56.
5) 日本呼吸器学会監, 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班特発性肺線維症の治療ガイドライン作成委員会編. 特発性肺線維症の治療ガイドライン 2017. 南江堂 ; 2017. p.37-9.
7) Nishino M, et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer : A Systematic Review and Meta-analysis. JAMA Oncol 2016 ; 2 : 1607-16.
9) Green RA, et al. Alkylating agents in bronchogenic carcinoma. Am J Med 1969 ; 46 : 516-25.
13) 峯岸裕司, 弦間昭彦. 特発性間質性肺炎合併進行/術後再発肺癌の二次治療以降の化学療法に関する実態調査-生存期間に関する追加調査. びまん性肺疾患に関する調査研究班. 平成25年度研究報告書. 2014. p.77-81.
P.356 掲載の参考文献
2) 千葉弘文, 高橋弘毅. 特発性間質性肺炎の疫学. Respiratory Medical Research 2014 ; 2 : 74-7.
7) Fujimoto T, et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis : surgical contraindication? Ann Thorac Surg 2003 ; 76 : 1674-8.
10) Fujimura A, et al. Pirfenidone plays a biphasic role in inhibition of epithelial-mesenchymal transition in non-small cell lung cancer. Lung Cancer 2017 ; 106 : 8-16.
12) Sato T, et al. A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients. Gen Thorac Cardiovasc Surg 2015 ; 63 : 164-72.
14) 厚生労働省科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班特発性肺線維症の治療ガイドライン作成委員会編. 特発性肺線維症の治療ガイドライン 2017. 南江堂 ; 2017. p.35.
15) 奥久司. ピルフェニドンの作用機序について. 医薬ジャーナル 2009 ; 45 : 120-5.
21) Rogliani P, et al. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis : A systematic review and meta-analysis. Pulm Pharmacol Ther 2016 ; 40 : 95-103.
22) 医療用医薬品 : オフェブ添付文書. http://www.kegg.jp/medicus-bin/japic_med?japic_code=00065741
25) 桑野和善ほか. 急性増悪に伴いびまん性肺胞出血をきたした特発性間質性肺炎の1剖検例. 日呼吸会誌 2001 ; 39 : 787-91.
26) Schwarz MI. Diffuse alveolar damage. In : Schwarz MI, King TE, eds. Interstitial Lung Disease. 3rd ed, BC Decker Inc ; 1998. p.535-58.
29) Crosby LK, et al. Balance of life and death in alveolar epithelial type II cells : proliferation, apoptosis, and the effects of cyclic stretch on wound healing. Am J Physiol Lung Cell Mol Physiol 2011 ; 301 : L536-46.

8章 ガイドラインの活用法と国際的整合性

P.367 掲載の参考文献
1) 厚生労働省科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班特発性肺線維症の治療ガイドライン作成委員会編. 特発性肺線維症の治療ガイドライン 2017. 南江堂 ; 2017.
3) American Thoracic Society ; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002 ; 165 : 277-304.
6) Raghu G, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012 ; 366 : 1968-77.
13) 相原守夫. 診療ガイドラインのためのGRADEシステム, 第2版. 凸版メディア ; 2015.
18) Minds診療ガイドライン選定部会監, 福井次矢ほか編. Minds診療ガイドライン作成の手引き 2007. 医学書院 ; 2007.

最近チェックした商品履歴

Loading...